NASDAQ:IMUX
Immunic Inc. Stock News
$1.29
+0.0450 (+3.61%)
At Close: May 20, 2024
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
06:30am, Thursday, 22'nd Feb 2024
– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Init
Immunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel Vitt
10:31am, Thursday, 15'th Feb 2024
The journey toward effective therapies for patients with multiple sclerosis (MS) is marked by persistent challenges. Despite advancements in addressing relapses, the specter of disability progression
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
06:30am, Thursday, 15'th Feb 2024
– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of oral
Immunic CSO highlights her role ahead of International Day of Women and Girls in Science
07:01am, Friday, 09'th Feb 2024
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof sheds light on her crucial role and the groundbreaking strides being made in the scientific world ahead of the International Day of Wo
Immunic announces up to $240M financing
07:24am, Friday, 05'th Jan 2024
Immunic Inc (NASDAQ:IMUX) shares took off after the biotechnology firm announced it would be raising up to $240 million in a private placement. Immunic stock was up 11.2% at US$1.58 before Friday's o
Immunic gets patent notice of allowance for lead asset to treat multiple sclerosis
08:46am, Tuesday, 21'st Nov 2023
Immunic, Inc. said the US Patent and Trademark Office has given it a notice of allowance for patent application 17/992,162 entitled entitled 'Compounds and Dosage Regimen for Use in the Prevention o
Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript
10:53am, Tuesday, 14'th Nov 2023
Immunic, Inc. (NASDAQ:IMUX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Wha
Immunic advances drug targeting progressive multiple sclerosis during 3Q
09:08am, Tuesday, 14'th Nov 2023
Immunic Inc (NASDAQ:IMUX) – a biotechnology company developing a pipeline of orally administered small molecule therapies for chronic inflammatory and autoimmune diseases - during the three months e
Immunic gets Notice of Allowance for US patent protecting treatment of relapsing MS with vidofludimus and salts
08:13am, Thursday, 02'nd Nov 2023
Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protecting the treatment of relapsing multiple sclerosis
Immunic presents data from Phase 2 study of vidofludimus calcium in relapsing-remitting MS
10:11am, Wednesday, 11'th Oct 2023
Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis
Immunic shares soar 48% after-hours buoyed by interim MS data
03:50am, Tuesday, 10'th Oct 2023
Shares in Immunic Therapeutics Inc. soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for�
Immunic to Participate in Industry and Investor Conferences in September
06:30am, Wednesday, 06'th Sep 2023
NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic completes enrollment in trial of vidofludimus calcium in patients with progressive MS
08:19am, Thursday, 17'th Aug 2023
Immunic Inc (NASDAQ:IMUX) said it has completed the enrollment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). A to
Immunic reports 2Q results; expects to be able to fund operations into 4Q 2024
09:18am, Thursday, 03'rd Aug 2023
Immunic, Inc. said that at the end of its second quarter to June 30, 2023, it had cash, cash equivalents and investments of $77.3 million with which it expects to be able to fund its operations into
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
06:30am, Thursday, 27'th Jul 2023
– Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK , July 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally ad